Galapagos (GLPG) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

GLPG · Stock Price

USD 27.73+2.41 (+9.52%)

Market Cap: $1.9B

Historical price data

Market Cap: $1.9BPipeline: 108 drugs (3 Phase 3)Patents: 20Founded: 1999HQ: Mechelen, Belgium

Sector Ranking#145 in Small Molecule Drugs #85 in Biologics / Biosimilars

Overview

Galapagos is a commercial-stage biotech transitioning from a platform-centric discovery model to a lean, externally-focused business development engine. Its legacy is anchored by the successful JAK1 inhibitor filgotinib (Jyseleca), developed with Gilead, which provides European revenue and royalties. The company's current strategy, under new leadership, involves winding down internal cell therapy to redeploy capital towards acquiring late-stage clinical assets in high-value therapeutic areas like oncology and immunology, as exemplified by its new T cell engager collaboration with Gilead.

Immunology & InflammationOncology

Technology Platform

Transitioning from legacy internal discovery platforms to a financial and business development-focused model for acquiring advanced clinical-stage therapeutics.

Pipeline

108

108 drugs in pipeline3 in Phase 3

Drug	Indication	Stage
Filgotinib + Adalimumab	Rheumatoid Arthritis	Approved
Filgotinib + Anti-Tumor Necrosis Factor Alpha Drug (Product)	Rheumatoid Arthritis	Approved
Filgotinib + Placebo	Ulcerative Colitis	Phase 3
GLPG1690 + Placebo	Idiopathic Pulmonary Fibrosis	Phase 3
GLPG1690 + Placebo	Idiopathic Pulmonary Fibrosis	Phase 3

Funding History

2

Total raised:$100M

PIPE$100MGilead SciencesJul 15, 2019

IPOUndisclosedUndisclosedMay 5, 2005

Opportunities

Galapagos has a unique opportunity to leverage its €3.7B+ cash reserve to act as a consolidator, acquiring de-risked, late-stage assets in large markets like oncology and immunology.

Its lean structure and experienced BD leadership position it to move quickly on attractive deals that could rapidly rebuild pipeline value.

Risk Factors

The primary risk is execution: failure to identify and successfully develop acquired assets would render the new strategy void.

A significant pipeline gap exists, and the commercial outlook for its sole product, Jyseleca, faces intense competition and class-wide safety concerns.

Competitive Landscape

As an acquirer, Galapagos competes with other biotech/pharma for high-quality assets. Its key advantages are a strong balance sheet and operational expertise. In immunology, Jyseleca competes with other JAK inhibitors and biologics in a crowded market.